Cost-effectiveness analysis for clinicians

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Hill, Suzanne R ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE; HUMAN; NOTE; QUALITY ADJUSTED LIFE YEAR; ARTICLE; ECONOMICS; HEALTH CARE DELIVERY; METHODOLOGY; PATIENT PREFERENCE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT PREFERENCE; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS;

EID: 84856397797     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-10     Document Type: Note

References (23)

1. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990, 113:147-154.
2. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L. Comparing impact and cost-effectiveness of primary prevention: strategies for lipid-lowering. Ann Intern Med 2009, 150:243-254.
3. Yong JHE, Schuh S, Rashidi R, Vanderby S, Lau R, Laporte A, Nauenberg E, Ungar WJ. A cost effectiveness analysis of omitting radiography in diagnosis of acute bronchiolitis. Pediatr Pulmonol 2009, 44:122-127. 10.1002/ppul.20948, 19142890.
4. North RB, Kidd D, Shipley J, Taylor RS. Spinal cord stimulation versus reoperation for failed back surgery syndrome: a cost effectiveness and cost utility analysis based on a randomized, controlled trial. Neurosurgery 2007, 61:361-369. 10.1227/01.NEU.0000255522.42579.EA, 17762749.
5. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-Effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009, 150:73-83.
6. Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?. Ann Intern Med 1992, 116:238-244.
7. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999, 282:1453-1457. 10.1001/jama.282.15.1453, 10535436.
8. Hill SR, Mitchell AS, Henry DA. Problems in the conduct of pharmacoeconomic evaluations. JAMA 2000, 283:2116-2121. 10.1001/jama.283.16.2116, 10791503.
9. Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003, 183:498-506. 10.1192/bjp.183.6.498, 14645020.
10. Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care 2010, 26:330-333. 10.1017/S0266462310000322, 20584363.
11. Hartmann M, Knoth H, Schulz D, Knoth S. Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations. Br J Cancer 2003, 89:1405-1408. 10.1038/sj.bjc.6601308, 2394350, 14562007.
12. Garattini L, De Compadri P, Clemente R, Cornago D. Economic evaluations in Italy: a review of the literature. Int J Technol Assess Health Care 2003, 19:685-691.
13. Jang S, Chae YK, Haddad T, Majhail NS. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res Treat 2010, 121:273-279. 10.1007/s10549-010-0870-7, 20352486.
14. Polyzos NP, Valachis A, Mauri D, Ioannidis JP. Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test. CMAJ 2011, 183:E337-343. 10.1503/cmaj.101506, 3071415, 21402681.
15. Peura PK, Martikainen JA, Purmonen TT, Turunen JH. Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review. Med Decis Making 2011,
16. Clemens K, Townsend R, Luscombe F, Mauskopf J, Osterhaus J, Bobula J. Methodological and conduct principles for pharmacoeconomic research Pharmaceutical Research and Manufacturers of America. Pharmacoeconomics 1995, 8:169-174. 10.2165/00019053-199508020-00008, 10155611.
17. Drummond M, Brown R, Fendrick AM, Fullerton P, Neumann P, Taylor R, Barbieri M, . ISPOR Task Force Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 2003, 6:407-416. 10.1046/j.1524-4733.2003.64245.x, 12859580, ISPOR Task Force.
18. Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, Sullivan SD. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008, 24:244-258. discussion 362-368.
19. Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development 2001, Geneva: WHO.
20. Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA 2005, 294:2618-2622. 10.1001/jama.294.20.2618, 16304076.
21. Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K. Searching for cost effectiveness thresholds in the NHS. Health Policy 2009, 91:239-245. 10.1016/j.healthpol.2008.12.010, 19168255.
22. Simoens S, Dooms M. How much is the life of a cancer patient worth? A pharmaco-economic perspective. J Clin Pharm Ther 2011, 36:249-256. 10.1111/j.1365-2710.2010.01181.x, 21545607.
23. Ioannidis JPA, Garber AM. Individualized cost-effectiveness analysis. PloS Med 2011, 8:e1001058. 10.1371/journal.pmed.1001058, 3134464, 21765810.